- |||||||||| Chirocaine (levobupivacaine) / Purdue, AbbVie
Review, Journal: Gene polymorphism impact on opioid analgesic usage. (Pubmed Central) - Sep 20, 2024 From those articles, we reviewed the impact of gene polymorphism on pain management and drug pharmacokinetics. Based on this systematic review, we concluded that gene polymorphism of gene affects analgesic, specifically opioid mechanisms.
- |||||||||| memantine / Generic mfg., amantadine / Generic mfg.
Journal: Discovery of hybrid Glypromate conjugates with neuroprotective activity against paraquat-induced toxicity. (Pubmed Central) - Sep 20, 2024 On the other hand, in SH-SY5Y differentiated cells, conjugate 18c functionalized with (R)-1-aminoindane counteracted the toxicity elicited by paraquat (p < 0.0001), while Glypromate was found to exacerbate the neurotoxicity. Altogether, this work adds new insights into Glypromate research by demonstrating that chemical conjugation and annular constriction are effective strategies to tune neuroprotective responses against different neurotoxic stimuli, paving the way for the development of new neurotherapeutics.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, Rexulti (brexpiprazole) / Lundbeck, Otsuka
Review, Journal, Adverse events: An updated safety review of the relationship between atypical antipsychotic drugs, the QTc interval and Torsades de Pointes: implications for clinical use. (Pubmed Central) - Sep 20, 2024 Agents such as ziprasidone and iloperidone are significantly more likely to prolong the QTc interval compared to others such as brexpiprazole, cariprazine, olanzapine, and clozapine. A personalized approach using low-risk medications when clinically feasible, and at the lowest efficacious dose, offers a promising path toward safer antipsychotic prescribing.
- |||||||||| ondansetron / Generic mfg.
Journal: Reply to the letter by Satici MH. (Pubmed Central) - Sep 20, 2024 No data was found to support the use of antidepressants in juvenile BD. No abstract available
- |||||||||| aripiprazole / Generic mfg., topiramate / Generic mfg.
Review, Journal: An update on the pharmacological management of Tourette syndrome and emerging treatment paradigms. (Pubmed Central) - Sep 20, 2024 The same holds true for vesicular monoamine transporter-2 inhibitors, as they are deemed to be safe and effective in real-world use and open-label trials despite not meeting primary endpoints in placebo-controlled trials. Cannabinoids may be considered in adults if the approaches above do not control tics.
- |||||||||| ondansetron / Generic mfg.
Journal: Letter to the article by Shirozu K, et al. (Pubmed Central) - Sep 20, 2024 Cannabinoids may be considered in adults if the approaches above do not control tics. No abstract available
- |||||||||| paroxetine / Generic mfg.
Journal: Paroxetine Effect on Nerve Growth Factor, Human Neurotrophin-4, Brain-Derived Neurotrophic Factor Levels in Post-stroke Depression. (Pubmed Central) - Sep 20, 2024 HAMD and NIHSS at T0 were compared; T1 and T2 were lower than T0, T2 was lower than T1, and observation group was lower (P?<?0.05); HAMD and NIHSS were compared among groups, time, and interaction (P?<?0.05). For post-stroke depression, paroxetine treatment can effectively improve NGF, NT-4, BDNF, 5-HT, Hcy, and NE levels and effectively reduce the degree of neurological damage and depression, which has high clinical application value.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment closed, Trial completion date, Trial primary completion date: Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia (clinicaltrials.gov) - Sep 20, 2024 P1/2, N=36, Active, not recruiting, Recruiting --> Completed Enrolling by invitation --> Active, not recruiting | Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: May 2024 --> Dec 2024
- |||||||||| ketamine / Generic mfg.
Trial completion date, Trial primary completion date: KetHead: Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches (clinicaltrials.gov) - Sep 20, 2024 P3, N=56, Recruiting, Enrolling by invitation --> Active, not recruiting | Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: May 2024 --> Dec 2024 Trial completion date: Feb 2024 --> Feb 2026 | Trial primary completion date: Oct 2023 --> Oct 2025
- |||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Blenrep (belantamab mafodotin-blmf) / GSK
Journal, Adverse events, Real-world evidence, Real-world: Drug-Related Keratitis: A Real-World FDA Adverse Event Reporting System Database Study. (Pubmed Central) - Sep 20, 2024 Identifying the specific risks and timing of drug-induced keratitis can support the development of preventive measures. Identifying the specific drugs related to medication-related keratitis is of significant importance for drug vigilance in the occurrence of drug-related keratitis.
- |||||||||| 5-methoxy-dimethyltryptamine dry-powder intranasal (BPL-003) / Beckley Psytech
Enrollment closed: An Open-Label, Single Dose Study in Patients with Alcohol Use Disorder (clinicaltrials.gov) - Sep 20, 2024 P2, N=13, Active, not recruiting, Identifying the specific drugs related to medication-related keratitis is of significant importance for drug vigilance in the occurrence of drug-related keratitis. Recruiting --> Active, not recruiting
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap, Qulipta (atogepant) / AbbVie
Retrospective data, Review, Journal, HEOR, Real-world evidence, Real-world: Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review. (Pubmed Central) - Sep 20, 2024 Recruiting --> Active, not recruiting This real-world study of patients with CM demonstrated that adding atogepant to onabotulinumtoxinA as a combination preventive treatment for CM was effective by providing an additional reduction in MHDs over?~?3 and?~?6
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Aphthasol (amlexanox) / Abeona Therap, Esteve, Lipaglyn (saroglitazar) / Zydus Lifesci
Review, Journal: Protein Kinases in Obesity, and the Kinase-Targeted Therapy. (Pubmed Central) - Sep 20, 2024 Co-treatment of antiobesity and antidiabetic herbal compound, berberine with antipsychotic drug olanzapine decreases the accumulation of triglyceride. While low-dose rapamycin, metformin, amlexanox, thiazolidinediones, and saroglitazar protect against insulin resistance, glucagon-like peptide-1 analog liraglutide inhibits palmitate-induced inflammation by suppressing mTOR complex 1 (mTORC1) activity and protects against lipotoxicity.
- |||||||||| lithium carbonate ER / Generic mfg.
Journal: Pharmacological Mechanism of Herbal Interventions for Bipolar Disorder. (Pubmed Central) - Sep 20, 2024 Though different treatments are available, like lithium, risperidone, valproic acid, etc., which are widely used, they come with certain limitations, including narrow therapeutic index, hypothyroidism, weight gain, extrapyramidal symptoms, etc. The interest in herbal- based treatments for bipolar disorder arises from the desire for alternative, potentially more natural, and holistic approaches with fewer side effects. The current review focuses on the potential effects of herbal drugs and their derivatives to alleviate the symptoms of bipolar disorder.
- |||||||||| Aduhelm (aducanumab) / Neurimmune, Eisai, Leqembi (lecanemab-irmb) / Biogen, Eisai, Kisunla (donanemab-azbt) / Eli Lilly
Journal: Recent Advances in the Treatment and Management of Alzheimer's Disease: A Precision Medicine Perspective. (Pubmed Central) - Sep 20, 2024 Another medication that can temporarily alleviate dementia symptoms is memantine, which blocks the N-methyl-D-aspartate (NMDA) receptor...For some Alzheimer's pa-tients, the FDA-approved monoclonal antibody, aducanumab, is an option; for others, phase 3 clinical studies are underway for drugs, like lecanemab and donanemab, which have demonstrat-ed potential in eliminating amyloid protein. However, additional study is required to identify and address these limitations in order to reduce the likelihood of side effects and maximize the thera-peutic efficacy.
- |||||||||| N-methyl amisulpride (LB-102) / LB Pharma
Enrollment closed: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia (clinicaltrials.gov) - Sep 20, 2024 P2, N=350, Active, not recruiting, However, additional study is required to identify and address these limitations in order to reduce the likelihood of side effects and maximize the thera-peutic efficacy. Recruiting --> Active, not recruiting
- |||||||||| Ibrance (palbociclib) / Pfizer, Xenical (orlistat) / Roche, GSK
Journal, Adverse events: Exploring the top 30 drugs associated with drug-induced constipation based on the FDA adverse event reporting system. (Pubmed Central) - Sep 20, 2024 The drug with the highest ranking was lenalidomide (7,730 cases, 4.55%), with the most prevalent drug class being antineoplastic and immunomodulating agents...However, four drugs (orlistat, nintedanib, palbociclib, and dimethyl fumarate) presented an unexpected risk of constipation. Ranked by signal values, sevelamer carbonate emerged as the drug with the strongest risk signal [reporting odds ratio (95% CI): 115.51 (110.14, 121.15); PRR (?2): 83.78 (191,709.73); EBGM (EB05): 82.63 (79.4); IC (IC025): 6.37 (4.70)]...The median TTO for orlistat was 3
- |||||||||| ondansetron intravenous / Generic mfg.
New P3 trial: A phase II, randomized, multicenter, dose-finding, positive control, placebo-controlled, double-blind, double-dummy clinical trial to evaluate the efficacy and safety of HRS5580 for injection in the prevention of postoperative nausea and vomiting (EUDRACT) - Sep 20, 2024 P3, N=232, Not yet recruiting,
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
New P1/2 trial: A multi-center, randomized, double-blind, placebo-controlled, and active-controlled phase I/II clinical trial to evaluate the safety, tolerability, immunogenicity, and efficacy of DN001 recombinant A-type botulinum toxin (DN001) for the treatment of moderate to severe glabellar lines. (EUDRACT) - Sep 20, 2024 P1/2, N=180, Not yet recruiting,
- |||||||||| amitriptyline / Generic mfg., nortriptyline / Generic mfg., tramadol hydrochloride / Generic mfg.
Journal: Application of a molecular networking approach using LC-HRMS combined with the MetWork webserver for clinical and forensic toxicology. (Pubmed Central) - Sep 20, 2024 Using MetWork, metabolites and parent drugs such as amitriptyline, its metabolite nortriptyline and amitriptyline glucuronide phase 2 metabolites were anticipated and proposed as putative annotations. The workflow increases confidence in toxicological screening by highlighting putative structures in biological matrices in combination with CFM-ID (Competitive Fragmentation Modeling for Metabolite Identification) and MetWork to extend the annotation of potential drugs even without a reference standard.
|